Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2702-2706

  Permar, Sallie R ^a   Fong, Youyi ^b   Vandergrift, Nathan ^a   Fouda, Genevieve G ^a   Gilbert, Peter ^b   Parks, Robert ^a   Jaeger, Frederick H ^a   Pollara, Justin ^a   Martelli, Amanda ^a   Liebl, Brooke E ^a   Lloyd, Krissey ^a   Yates, Nicole L ^a   Overman, R Glenn ^a   Shen, Xiaoying ^a   Whitaker, Kaylan ^a   Chen, Haiyan ^a   Pritchett, Jamie ^a   Solomon, Erika ^a   Friberg, Emma ^a   Marshall, Dawn J ^a   Whitesides, John F ^a   Gurley, Thaddeus C ^a   Von Holle, Tarra ^a   Martinez, David R ^a   Cai, Fangping ^a   Kumar, Amit ^a   Xia, Shi Mao ^a   Lu, Xiaozhi ^a   Louzao, Raul ^a   Wilkes, Samantha ^a   Datta, Saheli ^a   Sarzotti Kelsoe, Marcella ^a   Liao, Hua Xin ^a   Ferrari, Guido ^a   Alam, S Munir ^a   Montefiori, David C ^a   Denny, Thomas N ^a   Moody, M Anthony ^a   Tomaras, Georgia D ^a   Gao, Feng ^a   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY RESPONSE; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATERNAL PLASMA; PRIORITY JOURNAL; PROPENSITY SCORE; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; SECONDARY ANALYSIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; ANTIBODY SPECIFICITY; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFANT; MULTIVARIATE ANALYSIS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; RISK FACTOR; STATISTICAL MODEL; TRANSMISSION; VERTICAL TRANSMISSION;

GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT; VIRUS ANTIGEN;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; COHORT STUDIES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 84936797214     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81593     Document Type: Article

References (28)

1. Rossi P, et al. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci U S A. 1989;86(20):8055-8058.
2. Pancino G, et al. Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. J Infect Dis. 1998;177(6):1737-1741.
3. Markham RB, et al. Maternal IgG1 and IgA antibody to V3 loop consensus sequence and maternal-infant HIV-1 transmission. Lancet. 1994;343(8894):390-391.
4. Scarlatti G, et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis. 1993;168(1):207-210.
5. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol. 2006;80(13):6525-6533.
6. Wu X, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006;80(2):835-844.
7. Rainwater SM, et al. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res. 2007;5(2):189-197.
8. Goo L, Milligan C, Simonich CA, Nduati R, Overbaugh J. Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J Virol. 2012;86(18):9566-9582.
9. Chaillon A, et al. The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1. J Virol. 2012;86(19):10540-10546.
10. Lynch JB, et al. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol. 2011;85(11):5252-5261.
11. Omenda MM, et al. Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection. J Acquir Immune Defic Syndr. 2013;64(2):163-166.
12. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-1286.
13. Gottardo R, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013;8(9):e75665.
14. Rich KC, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics. 2000;105(1):e8.
15. Fong Y, Di C, Permar S. Change point testing in logistic regression models with interaction term. Stat Med. 2015;34(9):1483-1494.
16. Seaman MS, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439-1452.
17. Gilbert P, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis. 2010;202(4):595-605.
18. Klein F, et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med. 2014;211(12):2361-2372.
19. Bartlett JA, et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS. 1998;12(11):1291-1300.
20. Wright PF, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis. 1999;180(4):1080-1088.
21. Heckman JJ. Sample selection bias as a specification error. Econometrica. 1979;47(1):153-161.
22. Ugen KE, et al. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest. 1992;89(6):1923-1930.
23. Diomede L, et al. Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. J Virol. 2012;86(8):4129-4138.
24. Westfall PH, Young SS. P value adjustments for multiple tests in multivariate binomial models. J Am Stat Assoc. 1989;84(407):780-786.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B. 1975;57(1):289-300.
26. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46.
27. Kirchherr JL, et al. High throughput functional analysis of HIV-1 env genes without cloning. J Virol Methods. 2007;143(1):104-111.
28. Liao HX, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods. 2009;158(1-2):171-179.